This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Palivizumab “highly cost-effective” for RSV prevention. Pharmacoecon. Outcomes News 630, 10 (2011). https://doi.org/10.2165/00151234-201106300-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106300-00013